{
    "name": "lidocaine/tetracaine",
    "comment": "Rx",
    "other_names": [
        "Synera",
        "Pliaglis"
    ],
    "classes": [
        "Anesthetics",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/synera-pliaglis-lidocaine-tetracaine-343668",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to determine drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; available data from an epidemiologic study and case series with parenteral lidocaine use in pregnant women have not identified drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes",
            "Published data on tetracaine use in pregnant women are not sufficient to determine any drug-associated risks; the amount of lidocaine and tetracaine systemically absorbed is low compared to parenteral route of administration and is not expected to result in significant fetal exposure; systemic exposure of drug combination is directly related to both duration of application and surface area over which it is applied"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In a published animal reproduction study, pregnant rats administered lidocaine by continuous subcutaneous infusion during period of organogenesis resulted in lower fetal body weights at doses approximately 1.3 times the maximum recommended human dose (MRHD) during period of organogenesis",
                    "In published animal reproduction study, pregnant rats administered lidocaine, containing 1:100,000 epinephrine, injected into masseter muscle of the jaw or into gum of lower jaw on gestation Day 11 at 0.02 times MRHD resulted in developmental delays in neonates",
                    "Subcutaneous administration of tetracaine to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at 0.03 times the MRHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of tetracaine in human milk, effects on a breastfed infant, or on milk production; published studies on parenterally administered lidocaine have reported presence of lidocaine in human milk with milk:plasma ratios ranging between 0.4 to 1.1",
            "Available data on lidocaine’s effects on breastfed child have not revealed a consistent pattern of associated adverse effects; amount of lidocaine present in human milk following topical administration is unknown, but systemic absorption from topical lidocaine is low",
            "Consider developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or mother’s underlying condition",
            "Advise breastfeeding women not to apply drug combination directly to nipple and areola to avoid direct infant exposure"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug, components or PABA"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe hepatic or pseudocholinesterase deficiency",
                "Do not use on broken skin or mucous membranes",
                "Use caution if applied for longer period than recommended",
                "Produces mild localized warming of skin to facilitate drug absorption",
                "Simultaneous/successive patches not recommended due to risk of serious adverse effects caused by increased systemic absorption",
                "Do not apply near eyes as loss of protective reflexes can permit corneal irritation and potential abrasion",
                "Severe hepatic or pseudocholinesterase deficiency due to increased risk of toxic plasma concentrations of lidocaine/tetracaine",
                "Lidocaine and prilocaine have been shown to inhibit viral and bacterial growth",
                "Integrated heating component contains iron; remove patch prior to MRI",
                "Instruct patient to avoid irritating or exposing treated area to extreme temperatures until complete sensation has returned"
            ],
            "specific": [
                {
                    "type": "  Methemoglobinemia",
                    "description": [
                        "Use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly; patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition",
                        "Advise patients or caregivers to seek immediate medical attention if patient experiences the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue; discontinue Bicillin C-R and any other oxidizing agents; depending on severity of signs and symptoms, patients may respond to supportive care, including oxygen therapy and hydration; a more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bupivacaine liposome",
            "description": {
                "common": "lidocaine increases toxicity of bupivacaine liposome by Other (see comment). Contraindicated. \nComment: Do not admix with other local nonbupivacaine-based local anesthetics; admixing results in a rapid increase in free (unencapsulated) bupivacaine; may administer after waiting at least 20 minutes following local administration of lidocaine."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dofetilide",
            "description": {
                "common": "lidocaine increases effects of dofetilide by pharmacodynamic synergism. Contraindicated. Additive cardiac effects."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "lidocaine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "flibanserin",
            "description": {
                "common": "lidocaine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lomitapide",
            "description": {
                "common": "lidocaine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axitinib",
            "description": {
                "common": "lidocaine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosutinib",
            "description": {
                "common": "lidocaine increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "tetracaine, bupivacaine implant.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid additional local anesthetic administration within 96 hr following bupivacaine implantation. If use of additional local anesthetics is unavoidable based on clinical need, monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobimetinib",
            "description": {
                "common": "lidocaine will increase the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "tetracaine, acetaminophen. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "tetracaine, acetaminophen IV. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "tetracaine, acetaminophen rectal. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone increases levels of lidocaine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Higher doses of amiodarone (ie, 600 mg BID) were shown to significantly increase lidocaine levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amyl nitrite",
            "description": {
                "common": "tetracaine, amyl nitrite. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "lidocaine will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "lidocaine will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosutinib",
            "description": {
                "common": "bosutinib increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "lidocaine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "tetracaine, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "lidocaine will increase the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol, lidocaine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "tetracaine, chloroquine. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cigarette smoking",
            "description": {
                "common": "cigarette smoking will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Lidocaine plasma levels may be elevated, increasing the risk of toxicity. Monitor cardiac function and symptoms of toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "tetracaine, dapsone. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir increases levels of lidocaine by decreasing metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "disopyramide, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of arrhythmia, heart failure in predisposed pts."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "duvelisib will increase the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of lidocaine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, lidocaine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "lidocaine will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "fostamatinib will increase the level or effect of lidocaine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Concomitant use of fostamatinib may increase concentrations of P-gp substrates. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir will increase the level or effect of lidocaine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hawthorn",
            "description": {
                "common": "hawthorn increases effects of lidocaine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyaluronidase",
            "description": {
                "common": "hyaluronidase, tetracaine. Other (see comment). Use Caution/Monitor. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "lidocaine will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isosorbide dinitrate",
            "description": {
                "common": "tetracaine, isosorbide dinitrate. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isosorbide mononitrate",
            "description": {
                "common": "tetracaine, isosorbide mononitrate. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "ivacaftor increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lidocaine will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of lidocaine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "lomitapide increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefloquine",
            "description": {
                "common": "lidocaine will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "mexiletine will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "lidocaine will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "nirmatrelvir will increase the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution warranted. Monitor lidocaine therapeutic concentrations if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution warranted. Monitor lidocaine therapeutic concentrations if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitrofurantoin",
            "description": {
                "common": "tetracaine, nitrofurantoin. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin IV",
            "description": {
                "common": "tetracaine, nitroglycerin IV. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin PO",
            "description": {
                "common": "tetracaine, nitroglycerin PO. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin sublingual",
            "description": {
                "common": "tetracaine, nitroglycerin sublingual. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin topical",
            "description": {
                "common": "tetracaine, nitroglycerin topical. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin transdermal",
            "description": {
                "common": "tetracaine, nitroglycerin transdermal. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin translingual",
            "description": {
                "common": "tetracaine, nitroglycerin translingual. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroprusside sodium",
            "description": {
                "common": "tetracaine, nitroprusside sodium. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "lidocaine will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of lidocaine by  decreasing metabolism. Modify Therapy/Monitor Closely. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when coadministered with Viekira Pak"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "palbociclib",
            "description": {
                "common": "lidocaine will increase the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "tetracaine, phenobarbital. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "tetracaine, phenytoin. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pipemidic acid",
            "description": {
                "common": "pipemidic acid will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponatinib",
            "description": {
                "common": "ponatinib increases levels of lidocaine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primaquine",
            "description": {
                "common": "tetracaine, primaquine. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "lidocaine, procainamide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Either suppresses myocardial conduction by increasing electrical stimulation threshold of the ventricle and His-Purkinje fibers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "tetracaine, quinine. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "lidocaine will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "lidocaine will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevelamer",
            "description": {
                "common": "sevelamer decreases levels of lidocaine by increasing elimination. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smoking",
            "description": {
                "common": "smoking will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sonidegib",
            "description": {
                "common": "lidocaine will increase the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of sonidegib with moderate CYP3A4 inhibitors. If a moderate CYP3A inhibitor must be used, administer the moderate CYP3A inhibitor for <14 days and monitor closely for adverse reactions, particularly musculoskeletal adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, lidocaine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "tetracaine, sulfadiazine. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "tetracaine, sulfisoxazole. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "suvorexant",
            "description": {
                "common": "lidocaine will increase the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease suvorexant starting dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors"
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfentanil",
            "description": {
                "common": "lidocaine increases toxicity of alfentanil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "lidocaine increases toxicity of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "lidocaine increases toxicity of buprenorphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "lidocaine increases toxicity of buprenorphine buccal by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butorphanol",
            "description": {
                "common": "lidocaine increases toxicity of butorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "codeine",
            "description": {
                "common": "lidocaine increases toxicity of codeine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dextromoramide",
            "description": {
                "common": "lidocaine increases toxicity of dextromoramide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diamorphine",
            "description": {
                "common": "lidocaine increases toxicity of diamorphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "lidocaine increases toxicity of difenoxin hcl by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "lidocaine increases toxicity of diphenoxylate hcl by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dipipanone",
            "description": {
                "common": "lidocaine increases toxicity of dipipanone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "lidocaine increases toxicity of hydromorphone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levorphanol",
            "description": {
                "common": "lidocaine increases toxicity of levorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lily of the valley",
            "description": {
                "common": "lidocaine, lily of the valley.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meperidine",
            "description": {
                "common": "lidocaine increases toxicity of meperidine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methadone",
            "description": {
                "common": "lidocaine increases toxicity of methadone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "morphine",
            "description": {
                "common": "lidocaine increases toxicity of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "lidocaine increases toxicity of nalbuphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "opium tincture",
            "description": {
                "common": "lidocaine increases toxicity of opium tincture by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxycodone",
            "description": {
                "common": "lidocaine increases toxicity of oxycodone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "lidocaine increases toxicity of oxymorphone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "papaveretum",
            "description": {
                "common": "lidocaine increases toxicity of papaveretum by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentazocine",
            "description": {
                "common": "lidocaine increases toxicity of pentazocine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sufentanil",
            "description": {
                "common": "lidocaine increases toxicity of sufentanil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tapentadol",
            "description": {
                "common": "lidocaine increases toxicity of tapentadol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tramadol",
            "description": {
                "common": "lidocaine increases toxicity of tramadol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Localized erythema",
            "percent": "71"
        },
        {
            "name": "Localized blanching",
            "percent": "12"
        },
        {
            "name": "Localized edema",
            "percent": "12"
        },
        {
            "name": "Other application site reactions",
            "percent": "4"
        },
        {
            "name": "contact dermatitis",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "skin discoloration",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Application site reactions",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "N",
            "percent": null
        },
        {
            "name": "V",
            "percent": null
        },
        {
            "name": "Contact dermatitis",
            "percent": null
        },
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "Skin discoloration",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Allergic reaction",
            "percent": null
        },
        {
            "name": "Blister",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Vesiculobullous rash",
            "percent": null
        }
    ]
}